Peptide record

TPDB20076

Antibacterial Anticancer Antiviral Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB20076
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 20-aa standard-residue multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, AI4AVP, dbAMP 3.0, and other sources, with an available 3D structural model.
Sequence
GIKEFKRIVQRIKDFLRNLV
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C114H194N34O27
ACHMPSTWY
RIK
2473.01
11.46
6
2
9
+4
2.48
-0.225
126.50
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
0
A
3
R
1
N
1
D
0
C
1
E
1
Q
1
G
0
H
3
I
2
L
3
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 3 N: 1 D: 1 C: 0 E: 1 Q: 1 G: 1 H: 0 I: 3 L: 2 K: 3 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
20 reviewed residue count
C114H194N34O27 sequence-only estimate (linear, free termini)
2473.01 sequence-only estimate (linear, free termini)
11.46 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
2.48 sequence-only estimate (linear, free termini)
-0.225 sequence-only estimate (linear, free termini)
Evidence Records 12 records
Evidence 1 Activity

Activity

MIC
Antibacterial
2 µM

Target

E. faecium V284-17

Source & Reference

NA

Other

It inhibits HIV-1. Active against E. faecium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MI
Evidence 2 Activity

Activity

MIC
Antibacterial
2-4 µM

Target

Staphylococcus aureus USA300

Source & Reference

NA

Other

It inhibits HIV-1. Active against E. faecium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (
Evidence 3 Activity

Activity

MIC
Antibacterial
8 µM

Target

A. baumannii B28-16

Source & Reference

NA

Other

cium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (MIC > 32 uM), and E. coli E423-17 (MIC 32 uM). It also dispersed p
Evidence 4 Activity

Activity

MIC
Antibacterial
32 µM

Target

Escherichia coli E423-17

Source & Reference

NA

Other

6-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (MIC > 32 uM), and E. coli E423-17 (MIC 32 uM). It also dispersed preformed biofilms at 64 uM ( Zhang et al., 2021 ). Virus: inhibited H
Evidence 5 Activity

Activity

MIC
Antiviral
2 µM

Target

E. faecium V284-17

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
It inhibits HIV-1. Active against E. faecium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MI
Evidence 6 Activity

Activity

MIC
Antiviral
2-4 µM

Target

Staphylococcus aureus USA300

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

It inhibits HIV-1. Active against E. faecium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (
Evidence 7 Activity

Activity

MIC
Antiviral
8 µM

Target

A. baumannii B28-16

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

cium V284-17 (MIC 2 uM), S. aureus USA300 (MIC 2-4 uM), K-pneumoniae E406-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (MIC > 32 uM), and E. coli E423-17 (MIC 32 uM). It also dispersed p
Evidence 8 Activity

Activity

MIC
Antiviral
32 µM

Target

Escherichia coli E423-17

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

6-17 (MIC>32 uM). A. baumannii B28-16 (MIC 8 uM), P-aeruginosa E411-17 (MIC > 32 uM), and E. coli E423-17 (MIC 32 uM). It also dispersed preformed biofilms at 64 uM ( Zhang et al., 2021 ). Virus: inhibited H
Evidence 9 Activity

Activity

50% cell death
Toxicity
22.7 µM
Cytotoxic
50% cell death | 22.7 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 10 Activity

Activity

50% Cytotoxicity
Toxicity
>40 µM
Cytotoxic
50% Cytotoxicity | >40 | µM | target cell: Human primary macrophages

Target

Human primary macrophages

Source & Reference

NA
DBAASP
Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. | iScience | 2020
Evidence 11 Activity

Activity

30% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
30% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure and Activity of a Selective Antibiofilm Peptide SK-24 Derived from the NMR Structure of Human Cathelicidin LL-37. | Pharmaceuticals (Basel) | 2021
Evidence 12 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.18591279]CEM-SS cells:TC50=22.7 µM.(TC50:the concentration that reduced cell viability by 50%)

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2008 Sep 52(9):3438-40.